Expand REGN Menu
REGN MENU

REGN Latest Press Releases

-- May 13, 2024 --

Dupixent (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) Globe Newswire 1:00 AM

-- May 8, 2024 --

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks Globe Newswire 6:00 AM

-- May 6, 2024 --

Regeneron Announces Investor Conference Presentations Globe Newswire 4:05 PM

-- May 2, 2024 --

Regeneron Reports First Quarter 2024 Financial and Operating Results Globe Newswire 6:30 AM

-- April 29, 2024 --

EYLEA HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases Globe Newswire 7:00 AM

-- April 25, 2024 --

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases Globe Newswire 7:00 AM

-- April 24, 2024 --

Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO Globe Newswire 10:05 AM

-- April 22, 2024 --

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) Globe Newswire 5:54 PM

-- April 18, 2024 --

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN) Globe Newswire 5:03 PM

-- April 17, 2024 --

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm Globe Newswire 9:00 PM
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors Business Wire 2:15 PM

-- April 11, 2024 --

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Globe Newswire 1:15 PM

-- April 7, 2024 --

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Globe Newswire 4:00 PM

-- April 1, 2024 --

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024 Globe Newswire 4:05 PM

-- March 27, 2024 --

SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC Business Wire 9:00 AM

-- March 25, 2024 --

Regeneron Provides Update on Biologics License Application for Odronextamab Globe Newswire 7:00 AM

-- March 22, 2024 --

Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm Globe Newswire 1:20 PM

-- March 12, 2024 --

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization PRNewswire 11:55 PM
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization Globe Newswire 9:30 PM

-- March 11, 2024 --

Praluent (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol Globe Newswire 7:00 AM

-- March 8, 2024 --

EYLEA HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet Globe Newswire 7:00 AM

-- February 23, 2024 --

Press Release: Dupixent sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation Globe Newswire 1:00 AM
Dupixent (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation Globe Newswire 1:00 AM

-- February 21, 2024 --

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review Globe Newswire 7:00 AM

-- February 16, 2024 --

Press Release: Japan first in the world to approve Dupixent for chronic spontaneous urticaria (CSU) Globe Newswire 1:00 AM
Japan First in the World to Approve Dupixent (dupilumab) for Chronic Spontaneous Urticaria (CSU) Globe Newswire 12:59 AM

-- February 6, 2024 --

Regeneron Announces Investor Conference Presentations Globe Newswire 4:05 PM

-- February 2, 2024 --

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results Globe Newswire 6:30 AM
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma Globe Newswire 6:00 AM

-- January 30, 2024 --

Biotech Shares Soar Premarket On Sale Of R&D Assets Yolowire 9:36 AM
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs Globe Newswire 7:00 AM

-- January 25, 2024 --

Press Release: Dupixent FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Globe Newswire 2:30 PM
Dupixent (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) Globe Newswire 2:29 PM

-- January 24, 2024 --

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards PRNewswire 12:05 PM
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards Globe Newswire 12:00 PM

-- January 16, 2024 --

Dupixent (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement Globe Newswire 7:00 AM

-- January 8, 2024 --

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo (cemiplimab) in Multiple Countries PRNewswire 7:30 AM

-- January 5, 2024 --

Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 Globe Newswire 4:05 PM

-- December 18, 2023 --

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference Globe Newswire 4:05 PM